{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:38:43Z","timestamp":1792665523899,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003965","name":"Migraine Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ncl.2020.09.001","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T22:11:19Z","timestamp":1604700679000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine"],"prefix":"10.1016","volume":"39","author":[{"given":"Edoardo","family":"Caronna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal J.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2020.09.001_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/head.13281","article-title":"The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies","author":"Burch","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.001_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017","author":"James","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2020.09.001_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","author":"Goadsby","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/0333102417728873","article-title":"Distribution of CGRP and CGRP receptor components in the rat brain","author":"Warfvinge","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib5","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","author":"Cernuda-Moroll\u00f3n","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/cne.23828","article-title":"Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in\u00a0situ hybridization, immunofluorescence, and autoradiography","author":"Eftekhari","year":"2016","journal-title":"J\u00a0Comp Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib7","article-title":"Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion","author":"Eftekhari","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.ncl.2020.09.001_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","author":"Olesen","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2020.09.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)61626-8","article-title":"Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial","author":"Ho","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2020.09.001_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0b013e3181b87942","article-title":"Randomized, controlled trial of telcagepant for the acute treatment of migraine","author":"Connor","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/0333102411398399","article-title":"Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine","author":"Hewitt","year":"2011","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/0333102416653233","article-title":"A\u00a0phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","author":"Voss","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The achieve ii randomized clinical trial","author":"Lipton","year":"2019","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ncl.2020.09.001_bib14","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2020.09.001_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/0333102413500727","article-title":"BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial","author":"Marcus","year":"2014","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","author":"Croop","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2020.09.001_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","author":"Lipton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15 Sup","key":"10.1016\/j.ncl.2020.09.001_bib19","article-title":"Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b\/3 Study (S17.001)","volume":"92","author":"Goadsby","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib20","unstructured":"New Haven CBP. Biohaven achieves positive topline results in pivotal phase 2\/3 study of & vazegepant, the first and only intranasal CGRP receptor antagonist in clinical development for the acute treatment of migraine."},{"key":"10.1016\/j.ncl.2020.09.001_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: A randomised, double-blind, placebo-controlled, phase 2 trial","author":"Sun","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib22","article-title":"Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study","author":"Dodick","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib23","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study","author":"Bigal","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib24","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial","author":"Dodick","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/head.13327","article-title":"Use of most bothersome symptom as a coprimary endpoint in migraine clinical trials: a post-hoc analysis of the pivotal ZOTRIP randomized, controlled trial","author":"Dodick","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.001_bib26","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib27","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/j.1526-4610.2011.02052.x","article-title":"Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease","author":"Ho","year":"2012","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.001_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2011.246","article-title":"A\u00a0randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina","author":"Chaitman","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ncl.2020.09.001_bib30","article-title":"Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries","author":"Rubio-Beltran","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib32","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1705848","article-title":"A\u00a0controlled trial of erenumab for episodic migraine","author":"Goadsby","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2020.09.001_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of Fremanezumab compared with placebo for prevention of episodic migraine a randomized clinical trial","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ncl.2020.09.001_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.ncl.2020.09.001_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib37","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","author":"Silberstein","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2020.09.001_bib38","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.ncl.2020.09.001_bib39","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib40","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007856","article-title":"Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability","author":"Ford","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib41","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000544321.19316.40","article-title":"Fremanezumab for preventive treatment of migraine: Functional status on headache-free days","author":"VanderPluym","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/0333102418789072","article-title":"Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab","author":"Buse","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib43","first-page":"165","article-title":"75% responder rates provide improvement in HIT-6 scores from week 4 through 12 following a single infusion of ALD403, or placebo","volume":"88","author":"Dodick","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/head.13156","article-title":"Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines","author":"Cohen","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.001_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2020.09.001_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2020.09.001_bib47","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/head.13427","article-title":"100% response rate to galcanezumab in patients with episodic migraine: a post hoc analysis of the results from phase 3, randomized, double-blind, placebo-controlled EVOLVE-1 and EVOLVE-2 Studies","author":"Rosen","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.001_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/head.13443","article-title":"Analysis of initial nonresponders to galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE-1, EVOLVE-2, and REGAIN randomized, double-blind, placebo-controlled studies","author":"Nichols","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.001_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2018-320242","article-title":"Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: A post-hoc analysis","author":"Goadsby","year":"2019","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2020.09.001_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","author":"Schwedt","year":"2018","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.ncl.2020.09.001_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/0333102419854082","article-title":"Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine","author":"Ashina","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1193-2","article-title":"A\u00a0phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","author":"Camporeale","year":"2018","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2020.09.001_bib55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102420912726","article-title":"Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study","volume":"40","author":"Tepper","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: Effects after treatment termination","author":"Raffaelli","year":"2019","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.ncl.2020.09.001_bib57","doi-asserted-by":"crossref","unstructured":"Detke H, Pozo-Rosich P, Reuter U, et al. Aurora Neurology Apr 2019;92(15 Supplement):10-010.","DOI":"10.1212\/WNL.92.15_supplement.P2.10-010"},{"key":"10.1016\/j.ncl.2020.09.001_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2017.01.009","article-title":"Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis","author":"Hong","year":"2017","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ncl.2020.09.001_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/0333102419888222","article-title":"Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions","author":"Ashina","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.001_bib60","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004391","article-title":"Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study","author":"Ashina","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/head.13316","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina","author":"Depre","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.001_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/0333102418776017","article-title":"Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers","author":"de Hoon","year":"2019","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.001_bib63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/head.13682","article-title":"Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial","volume":"60","author":"Ailani","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.001_bib64","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","author":"Sacco","year":"2019","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.ncl.2020.09.001_bib65","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice","year":"2019","journal-title":"Headache"},{"issue":"13","key":"10.1016\/j.ncl.2020.09.001_bib66","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.001_bib67","unstructured":"Eli Lilly and Company. A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD)."},{"key":"10.1016\/j.ncl.2020.09.001_bib68","unstructured":"Amgen. Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (OASIS (CM))."},{"key":"10.1016\/j.ncl.2020.09.001_bib69","doi-asserted-by":"crossref","DOI":"10.1095\/biolreprod67.2.624","article-title":"Infusion of pregnant rats with calcitonin gene-related peptide (CGRP)8-37, a CGRP receptor antagonist, increases blood pressure and fetal mortality and decreases fetal growth1","author":"Gangula","year":"2002","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ncl.2020.09.001_bib70","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00140.2003","article-title":"Involvement of calcitonin gene-related peptide in control of human fetoplacental vascular tone","author":"Dong","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ncl.2020.09.001_bib71","unstructured":"Allergan announces completion of two positive safety studies for ubrogepant \u2013 An oral CGRP receptor antagonist for the acute treatment of migraine."},{"key":"10.1016\/j.ncl.2020.09.001_bib72","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2017.3859","article-title":"Effect of different doses of Galcanezumab vs Placebo for episodic migraine prevention a randomized clinical trial","author":"Skljarevski","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib73","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib75","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study","author":"Bigal","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.001_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial","author":"Dodick","year":"2019","journal-title":"Cephalalgia"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:19:10Z","timestamp":1760005150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861920300682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0733861920300682"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2020.09.001","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2020.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}